Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jan 28, 2009; 15(4): 449-456
Published online Jan 28, 2009. doi: 10.3748/wjg.15.449
Published online Jan 28, 2009. doi: 10.3748/wjg.15.449
Table 3 Response rates
| Treatment group | ||
| CAPIRI (n = 17) number (%) patients | CAPIRI-Bev (n = 29) number (%) patients | |
| Tumor control rate (CR + PR + SD) | 13 (70.6) | 22 (75.9) |
| Complete response (CR) | - | - |
| Partial response (PR) | 5 (29.4) | 10 (34.5) |
| Stable disease (SD) | 7 (41.2) | 12 (41.4) |
| Progressive disease (PD) | 5 (29.4) | 6 (20.7) |
| Not rated | - | 1 (3.4) |
- Citation: Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, Hoehler T, Galle PR, Kanzler S. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009; 15(4): 449-456
- URL: https://www.wjgnet.com/1007-9327/full/v15/i4/449.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.449